Ace the CPHON Challenge 2025 – Elevate Your Pediatric Oncology Nursing Game!

In the context of Autoimmune Hemolytic Anemia (AIHA), the presence of increased antibodies on red blood cells is indicative of rapid destruction of these cells. When the immune system mistakenly identifies red blood cells as foreign entities, it produces antibodies that bind to these cells. This binding can lead to the activation of the complement system and the subsequent destruction of the red blood cells, primarily in the spleen and the liver.

This process explains why in AIHA, patients often exhibit signs and symptoms associated with hemolysis, which includes anemia, jaundice, and elevated levels of lactate dehydrogenase (LDH) in the blood. The increase in antibodies signifies that the immune response is actively targeting red blood cells, resulting in their premature destruction and a shortened lifespan.

In contrast, the options that discuss increased RBC lifespan, higher oxygen transport capacity, or increased platelet count are not relevant to the mechanism of hemolysis in this condition. In AIHA, the focus is on the rapid deterioration of red blood cells rather than any improvements or increases in their function or count.